Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response

Figure 6

External validation of the applicability of the signature in ICGC HCC cohort. (a) Kaplan-Meier analysis of OS of patients of high-risk subgroup and low-risk subgroup in ICGC cohort. (b) AUC of risk signature in predicting 1-year, 3-year, and 5-year OS in HCC patients.

(a)

(b)